基于PET/CT的肿瘤内异质性定量预测乳腺癌新辅助化疗后病理完全缓解:多中心研究
本研究从治疗前18F-FDG PET/CT图像中提取肿瘤内生态多样性特征构建ITH指数,并结合影像组学评分与临床病理变量建立ICR-COME模型。多中心回顾性纳入323例乳腺癌患者,模型预测pCR的AUC在训练组为0.95、外部测试组B和C分别为0.87和0.88,优于临床病理模型和常规影像组学模型。
要点
- ICR-COME整合ITH指数、影像组学评分和临床病理变量,预测pCR性能优于传统模型。
- 三个队列中预测为非pCR的患者预后较差(P<0.05,log-rank检验)。
- 高ICR-COME评分与免疫细胞浸润增加及免疫相关通路激活相关。
核心结论
- ICR-COME对乳腺癌新辅助化疗后pCR和预后具有较强预测性能。
研究设计与样本
- 回顾性多中心研究,纳入2013至2025年间四家医院接受NAC的乳腺癌患者323例(中位年龄51岁±10)。
- 从治疗前18F-FDG PET/CT图像提取肿瘤内生态多样性特征和全肿瘤影像组学特征,分别构建ITH指数和影像组学评分。
- 采用逻辑回归筛选与pCR相关变量,整合临床病理特征、影像组学评分和ITH指数建立ICR-COME模型。
- 使用ROC、校准曲线和DCA评估模型性能与临床效用,Kaplan–Meier分析评估预后差异,对12例患者RNA测序数据探索生物学基础。
主要发现
- ICR-COME预测pCR的AUC在训练组为0.95,外部测试组B和C分别为0.87和0.88。
- ICR-COME显著优于临床病理模型和常规18F-FDG PET/CT影像组学模型(均P<0.05,DeLong检验)。
- 校准曲线和DCA显示ICR-COME具有满意的一致性和最大的临床净获益。
- 三个队列中预测为非pCR的患者预后较差(P<0.05,log-rank检验)。
- RNA测序和多重组化免疫荧光分析显示高ICR-COME评分与免疫细胞浸润增加及免疫相关通路激活增强相关。
关键数值与推荐
- ICR-COME模型预测pCR的AUC:训练组0.95,外部测试组B 0.87,外部测试组C 0.88。
- ICR-COME与临床病理模型和常规影像组学模型比较均P<0.05(DeLong检验)。
- 预测非pCR组预后较差,P<0.05(log-rank检验)。
临床怎么用
- 基于治疗前18F-FDG PET/CT的ICR-COME模型可用于乳腺癌NAC前无创预测pCR,辅助治疗决策。
- 模型预测为非pCR的患者预后较差,提示需更密切随访或强化治疗策略。
- 高ICR-COME评分与免疫浸润相关,可能为免疫治疗联合策略提供参考。
局限性
- 回顾性研究设计。
- 生物学机制探索仅基于12例患者的RNA测序数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop a quantitative measure of intratumoral heterogeneity (ITH) from pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) images and to evaluate its potential for predicting pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC). MATERIALS AND METHODS: This retrospective study included patients with BC who underwent NAC at four hospitals between 2013 and 2025. Tumour regions on pretreatment 18F-FDG PET/CT images were clustered to extract intratumoral ecological diversity features, while radiomic features were extracted from the entire tumour. Output probabilities from imaging-based extreme gradient boosting (XGBoost) models were used to generate an ITH index and a radiomics score, respectively. Logistic regression analysis was performed to identify variables associated with pCR. Significant variables, including clinicopathologic characteristics, radiomics score, and ITH index, were integrated into a combined predictive model (ICR-COME). Model performance and clinical utility were evaluated using receiver operating characteristic, calibration curve, and decision curve analyses (DCA). Survival differences between predicted pCR and non-pCR groups were assessed using Kaplan–Meier analysis. RNA sequencing data from 12 patients were analysed to further explore the biological basis of ICR-COME. RESULTS: The study included 323 women (median age, 51 years ± 10[SD]). For predicting pCR in BC patients, ICR-COME achieved the area under the receiver operating characteristic curve (AUC) values of 0.95 in the training cohort and 0.87 and 0.88 in external test cohorts B and C, respectively, which were significantly superior to those of the clinicopath model and the conventional radiomics model using 18F-FDG PET/CT (all P < 0.05, DeLong test). Calibration curve and DCA indicated that ICR-COME achieved satisfactory concordance and provided the greatest clinical net benefit. Patients in all three cohorts predicted as non-pCR exhibited poorer prognosis (P < 0.05, log-rank test). Furthermore, RNA sequencing and multiplex immunofluorescence analyses revealed that high ICR-COME scores were associated with increased immune cell infiltration and enhanced activation of immune-related pathways. CONCLUSIONS: ICR-COME, which integrates the ITH index, the radiomics score, and clinicopathologic variables, demonstrated strong predictive performance for pCR to NAC and prognosis in BC patients.
引用
- Zhang J, Yu X, Li X, et al. PET/CT-based quantification of intratumoral heterogeneity for predicting pathological complete response in breast cancer patients treated with neoadjuvant chemotherapy: A multicentre study. Eur J Nucl Med Mol Imaging. 2026. PMID: 41699278. doi:10.1007/s00259-026-07787-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。